Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC15295 structure
    GC15295AUY922 (NVP-AUY922)
    CAS: 747412-49-3
    纯度: >99.50% / >98.00%

    AUY922 (NVP-AUY922)是一种高效且选择性的 HSP90抑制剂,对 HSP90α和 HSP90β的 IC 50 值分别为 13nM和 21nM。

  • GC15315 structure
    GC15315Scriptaid
    CAS: 287383-59-9
    纯度: >98.50%

    HDAC inhibitor

  • GC15344 structure
    GC15344SP 600125
    CAS: 129-56-6
    纯度: >98.00%

    SP 600125是一种具有口服活性的、可逆的、具有选择性的ATP竞争性JNK 抑制剂,对JNK1、JNK2和JNK3的IC 50 分别为40、40和90nM。SP 600125常用于卵巢癌、肿瘤、帕金森病 (PD)、乳腺癌和哮喘的研究。

  • GC15364 structure
    GC15364L-685,458
    CAS: 292632-98-5
    纯度: >99.00%

    A γ-secretase inhibitor

  • GC15375 structure
    GC15375PFI-1 (PF-6405761)
    CAS: 1403764-72-6
    纯度: >99.50%

    A BET bromodomain inhibitor

  • GC15394 structure
    GC15394CBL0137 (hydrochloride)
    CAS: 1197397-89-9
    纯度: >98.00%

    CBL0137 (hydrochloride)是一种来自curaxins小分子家族的水溶性且代谢稳定的非遗传毒性抗癌药物,可以激活p53并抑制NF-κB,EC 50 值分别为0.37和0.47μM。

  • GC15399 structure
    GC15399Dp44mT
    CAS: 152095-12-0
    纯度: >98.00%

    An iron chelator with antiproliferative effects

  • GC15446 structure
    GC15446Ionomycin free acid
    CAS: 56092-81-0
    纯度: {{1-15}>98.00%}

    Ionomycin free acid 是一种选择性的强效钙离子载体,可作为活性 Ca2+ 载体。

  • GC15457 structure
    GC15457Pyridoxine
    CAS: 65-23-6
    纯度: >98.00% / >99.50%

    A 4-methanol form of vitamin B 6

  • GC15462 structure
    GC15462ISRIB (trans-isomer)
    CAS: 1597403-47-8
    纯度: >99.00%

    ISRIB (trans-isomer)是一种选择性抑制整合应激反应(ISR)通路的小分子化合物。ISRIB (trans-isomer)是PERK的一种高度选择性抑制剂,IC 50 为5nM。

  • GC15485 structure
    GC15485LY 294002
    CAS: 154447-36-6
    纯度: >98.00%

    LY294002是第一个合成的PI3Kα、δ和β抑制剂。

  • GC15503 structure
    GC15503NSC 687852 (b-AP15)
    CAS: 1009817-63-3
    纯度: >98.50%

    An inhibitor of the deubiquitinases USP14 and UCHL5

  • GC15550 structure
    GC15550Lacidipine
    CAS: 103890-78-4
    纯度: >99.50%

    An L-type calcium channel blocker

  • GC15568 structure
    GC15568Dasatinib (BMS-354825)
    CAS: 302962-49-8
    纯度: >99.50% / >98.00%

    Dasatinib (BMS-354825)是一种高效、口服生物利用度高的多靶点酪氨酸激酶抑制剂,对BCR-ABL、SRC家族激酶、c-KIT和PDGFR-β的IC₅₀分别为0.4nM、0.5nM、100nM和180nM。

  • GC15571 structure
    GC15571SU 9516
    CAS: 377090-84-1
    纯度: >99.50%

    A pro-apoptotic Cdk2/cyclin A inhibitor

  • GC15573 structure
    GC15573GSK481
    CAS: 1622849-58-4
    纯度: >98.00%

    A selective inhibitor of RIP1

  • GC15578 structure
    GC15578Dienogest
    CAS: 65928-58-7
    纯度: >98.00%

    A synthetic progestin and PR agonist

  • GC15586 structure
    GC15586AP1903
    CAS: 195514-63-7
    纯度: >98.00%

    AP1903是一种二价"二聚化"化合物,可与FKBP结合并诱导Fas交联。

  • GC15589 structure
    GC15589WHI-P154
    CAS: 211555-04-3
    纯度: >99.00%

    A JAK3 inhibitor

  • GC15603 structure
    GC15603JIB-04
    CAS: 199596-05-9
    纯度: >98.00%

    JIB-04是一种泛选择性Jumonji组蛋白去甲基化酶抑制剂,对JARID1A、JMJD2E、JMJD3、JMJD2A、JMJD2B、JMJD2C和JMJD2D的IC 50 值分别为230nM、340nM、855nM、445nM、435nM、1100nM和290nM。

  • GC15605 structure
    GC15605Ezetimibe
    CAS: 163222-33-1
    纯度: >99.50% / >99.00%

    Ezetimibe是一种选择性胆固醇吸收抑制剂,对肺癌细胞(A549)和人胚肾细胞(HEK293)的IC 50 为50µM,对黑色素瘤细胞(A375)的IC 50 为30µM,作用时间均为48h。

  • GC15613 structure
    GC15613p-nitro-Cyclic Pifithrin-α
    CAS: 60477-38-5
    纯度: >99.00%

    A cell-permeable form of cyclic PFT-α

  • GC15617 structure
    GC15617Etoposide
    CAS: 33419-42-0
    纯度: >99.50% / >99.00% / >98.50%

    Etoposide(VP-16)是一种非特异性拓扑异构酶II(Topoisomerase II)抑制剂,IC 50 值为59.2 μM。

  • GC15632 structure
    GC15632YM-155 hydrochloride
    CAS: 355406-09-6

    A survivin inhibitor